Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CRHBP | P24387 | 2/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103524 | 0.88 | — | — | |
| SCHEMBL3417718 | 0.74 | SMN1; SMN2 (0.48) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL9174815 | 0.74 | — | — | |
| SCHEMBL106757 | 0.73 | ITGB2 (0.41) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL106439 | 0.72 | ITGB2 (0.30) | ITGB2ICAM1ITGAL | |
| SCHEMBL3871811 | 0.72 | ITGB2 (0.35) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL2886599 | 0.70 | ITGB2 (0.52) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL21462 | 0.68 | ITGB2 (0.50) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL106440 | 0.68 | ABCG2 (0.39) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL1230573 | 0.68 | TSHR (0.36) | CLK1DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4554364-B2 | — | — | 2010-09-29 | — | — | JP | claimed |
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1539739-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-15 | — | — | EP | claimed |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-11-18 | — | — | US | claimed |
| EP-1449835-A2 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | claimed |
| EP-1247804-A1 | Pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-09 | — | — | EP | claimed |
| EP-1113801-A4 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-02 | — | — | EP | claimed |
| JP-2002524518-A | — | — | 2002-08-06 | — | — | JP | claimed |
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-21 | — | — | US | claimed |
| US-6124306-A | Thioalkyl alpha substituted pyrimidine compounds | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-26 | — | — | US | claimed |
| EP-1034167-A1 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-13 | — | — | EP | claimed |
| US-6043248-A | VIRICIDES FOR TREATING AN INDIVIDUAL INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | claimed |
| WO-2000015230-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| US-5981537-A | USEFUL IN THE TREATMENT OF INDIVIDUALS WHO ARE HIV POSITIVE | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-09 | — | — | US | claimed |
| WO-1999019304-A2 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-22 | — | — | WO | claimed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | claimed |
| EP-0728130-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-28 | — | — | EP | claimed |
| WO-1995013267-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | THE UPJOHN COMPANY (US) | 1995-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | ITGB2 3609/4885ICAM1 3185/4885ITGAL 4001/4885 |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | ITGB2 3609/4885ICAM1 3185/4885ITGAL 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.